Physician profile
Mark Peicher
NPI 1821676537
$3,621.80
in general payments reported to CMS, 2019-2025
17 companies · $1,901 in 2025
The $1,901 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $664 · 2024: $1,057 · 2025: $1,901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,523 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,522.80 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $849.68 | 2023-2025 | |
| Ardelyx, INC. | $432.52 | 2023-2025 | Ibsrela |
| Gilead Sciences, INC. | $411.83 | 2024-2025 | Livdelzi |
| Takeda Pharmaceuticals U.S.A., INC. | $282.72 | 2024-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $269.75 | 2025 | Xifaxan |
| Ipsen Biopharmaceuticals, INC | $191.64 | 2024-2025 | Iqirvo |
| Mallinckrodt Hospital Products INC. | $182.46 | 2024-2025 | Terlivaz |
| Janssen Biotech, INC. | $157.66 | 2025 | Tremfya |
| Enterra Medical, INC. | $146.96 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $132.82 | 2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $119.73 | 2023 | Rebyota |
| Exelixis INC. | $116.37 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.20 | 2023 | |
| Phathom Pharmaceuticals, INC. | $95.05 | 2024 | Voquezna |
| Aimmune Therapeutics, INC. | $79.31 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $29.43 | 2025 | Tukysa, Braftovi |
| Mirum Pharmaceuticals, INC. | $21.67 | 2025 | Livmarli |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Peicher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.